<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879020</url>
  </required_header>
  <id_info>
    <org_study_id>TA-8995-E02</org_study_id>
    <nct_id>NCT01879020</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects</brief_title>
  <official_title>A Randomised Double-blind, Placebo-controlled, Ascending-dose, Phase I Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests (haematology, biochemistry and urinalysis)</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs (supine systolic and diastolic blood pressure, heart rate and body temperature)</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration (AUC) versus time curve over the final dosing interval (AUC0-τ, Steady-state)</measure>
    <time_frame>7 days post the final dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The last time point 't' with a concentration Ct ≥ Lower limit quantification (LLQ) (AUC0-t, Steady-state)</measure>
    <time_frame>7 days post the final dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cholesterol ester transfer protein (CETP) activity (%)</measure>
    <time_frame>7 days post the final dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CETP concentration (mg/mL)</measure>
    <time_frame>4 hours after the first and the fibal dose</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>TA-8995 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TA-8995 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TA-8995 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TA-8995 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TA-8995 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TA-8995 1mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TA-8995 2.5mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TA-8995 5mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TA-8995 10mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TA-8995 25mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>Drug: TA-8995 1mg</description>
    <arm_group_label>TA-8995 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>Drug: TA-8995 2.5mg</description>
    <arm_group_label>TA-8995 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>Drug: TA-8995 5mg</description>
    <arm_group_label>TA-8995 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>Drug: TA-8995 10mg</description>
    <arm_group_label>TA-8995 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>Drug: TA-8995 25mg</description>
    <arm_group_label>TA-8995 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (TA-8995 1mg)</description>
    <arm_group_label>Placebo (TA-8995 1mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (TA-8995 2.5mg)</description>
    <arm_group_label>Placebo (TA-8995 2.5mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (TA-8995 5mg)</description>
    <arm_group_label>Placebo (TA-8995 5mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (TA-8995 10mg)</description>
    <arm_group_label>Placebo (TA-8995 10mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (TA-8995 25mg)</description>
    <arm_group_label>Placebo (TA-8995 25mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Free from any clinically significant illness or disease as determined by their medical
             history, physical examination, laboratory and other tests and as judged by the
             Investigator.

          -  Between 18 - 55 years old.

          -  Male of Caucasian ethnic origin.

          -  Body mass index (BMI) in the range of 19 - 33 kg/m² and had a minimum weight of 50 kg.
             Subjects with a BMI in the range 30.0 - 33.0 kg/m² had to have a waist measurement of
             ≤ 91 cm.

        Exclusion Criteria:

          -  High density lipoprotein (HDL)-C level of greater or equal to 2.59 mmol/L (≥ 100
             mg/dL) at Screening.

          -  Abnormal Electrocardiogram (ECG) at Screening or Day -1 including a QTc ≥ 430 ms (The
             QTc-interval was calculated automatically according to Bazett's formula. In the case
             of results of ≥ 430 ms, QTc was additionally calculated manually using Fridericia's
             formula which was used as an exclusion criterion).

          -  Family history of long QT syndrome, hypokalaemia or Torsades de Pointes

          -  Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes
             mellitus, coronary heart disease or history of any psychotic illness

          -  Presence or history of gastro-intestinal, hepatic or renal disease or any other
             condition known to interfere with the absorption, distribution, metabolism or
             excretion of drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Weber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Momentum Pharma Services GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Momentum Pharma Services GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22769</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>June 12, 2013</last_update_submitted>
  <last_update_submitted_qc>June 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MT-8995</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Cholesteryl ester transfer proteins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

